J&J Unit Aims To Thwart Sandoz's Generic Doribax

Law360, New York (December 15, 2011, 2:53 PM EST) -- Johnson & Johnson unit Janssen Pharmaceuticals Inc. slapped Sandoz Inc. with a patent infringement lawsuit Tuesday in New Jersey federal court in an effort to keep the company from marketing its own version of the injectable antibiotic Doribax.

Janssen lodged the suit after Sandoz filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking permission to manufacture a generic version of doripenem for injection, which Janssen sells as Doribax, according to the pharmaceutical company's complaint.

Doribax is used to treat intra-abdominal and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.